Dayvigo (Lemborexant) Post-Bariatric Surgery Use: Clinical Guide
A physician-level review of lemborexant (Dayvigo) pharmacokinetics, dosing, and safety after bariatric surgery, with primary-literature citations and clinical decision frameworks.
Lemborexant V2
24 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
24articles
5topic areas covered
Jul 14, 2025latest review
Lemborexant V2 library
Showing 24 of 24 clinical reviews.
Dayvigo Appetite & Cravings Changes: What the Evidence Actually Shows
Does lemborexant (Dayvigo) affect appetite or cravings? A clinical review of orexin biology, SUNRISE trial data, and real-world patterns in patients taking this dual orexin receptor antagonist for insomnia.
Dayvigo Autoimmune Disease Considerations: What Clinicians and Patients Need to Know
A clinical deep-dive into lemborexant (Dayvigo) use in autoimmune disease, covering orexin system immunology, drug interactions with DMARDs and biologics, sleep architecture effects, and dosing guidance for patients with rheumatoid arthritis, lupus, MS, and IBD.
Dayvigo Bone Health and Density Impact: What the Evidence Shows
A clinical review of lemborexant (Dayvigo) and its effects on bone health and density, including orexin biology, comparative data from benzodiazepine and Z-drug studies, fall-fracture risk, and practical guidance for prescribers managing older patients with insomnia.
Dayvigo Cancer Risk Signal Review: What the Evidence Actually Shows
A physician-level review of lemborexant (Dayvigo) and cancer risk signals. Covers FDA labeling, postmarket surveillance, orexin biology, clinical trial data, and how to counsel patients asking about the Dayvigo cancer risk signal.
Dayvigo Cardiovascular Impact Long-Term: What the Evidence Shows
A clinician-level review of lemborexant (Dayvigo) cardiovascular safety data, including blood pressure, heart rate, QTc, and long-term outcomes from SUNRISE-1, SUNRISE-2, and post-market surveillance.
Dayvigo Cognitive Function Impact: What the Clinical Evidence Shows
A physician-reviewed deep dive into how lemborexant (Dayvigo) affects next-morning cognition, driving performance, and memory, with primary-literature citations from SUNRISE-1 and beyond.
Dayvigo Compounded vs. Branded: A Clinical Comparison of Lemborexant
A physician-level comparison of compounded lemborexant vs. Branded Dayvigo covering pharmacology, clinical trial evidence, regulatory status, dosing, cost, and safety for patients and prescribers.
Dayvigo Evidence Base Graded by GRADE: What the Clinical Trials Actually Show
A GRADE-level analysis of lemborexant (Dayvigo) clinical evidence, covering SUNRISE-1, SUNRISE-2, head-to-head comparators, safety data, and what each finding means for prescribing decisions.
Dayvigo Hair and Skin Changes: What the Evidence Actually Shows
Does lemborexant (Dayvigo) cause hair loss or skin changes? A clinician-reviewed deep dive into the pharmacology, clinical trial data, and post-marketing reports to help you weigh the real risks.
Dayvigo Liver Function Impact: What the Clinical Evidence Shows
A physician-reviewed deep dive into how lemborexant (Dayvigo) affects liver function, hepatic metabolism, and ALT/AST levels, with primary-literature citations and dosing guidance for patients with hepatic impairment.
Dayvigo Mental Health and Mood Impact: What the Evidence Shows
A clinician-level review of lemborexant (Dayvigo) and its effects on mood, anxiety, depression, and next-day cognitive function, drawing on SUNRISE-1, FDA labeling, and current sleep-psychiatry literature.
Dayvigo Metabolism and Energy Expenditure: What Clinicians Need to Know
A physician-level review of lemborexant (Dayvigo) metabolism, CYP3A4 pharmacokinetics, and effects on energy expenditure, thermogenesis, and orexin-pathway physiology.
Dayvigo Microdosing Protocols: What the Evidence Actually Shows
A physician-reviewed deep dive into lemborexant (Dayvigo) microdosing protocols, covering FDA-approved dosing, the SUNRISE trial data, off-label sub-threshold use, pharmacokinetics, and what clinicians need to know before adjusting doses below 5 mg.
Dayvigo Muscle Preservation Strategies: A Clinical Guide to Lemborexant and Skeletal Muscle Health
A physician-reviewed guide to lemborexant (Dayvigo) muscle preservation strategies, covering orexin biology, sleep architecture effects on protein synthesis, and practical protocols for patients at risk of sarcopenia.
Dayvigo Plateau & Non-Response Troubleshooting
MD/PharmD-level guide to diagnosing and managing lemborexant (Dayvigo) plateau and non-response: dose optimization, comorbidity review, combination strategies, and when to switch agents.
Dayvigo Pre-Surgery Hold Window: How Long Before the OR?
A physician-level guide to the lemborexant (Dayvigo) pre-surgery hold window: pharmacokinetics, anesthesia interactions, CNS depression risk, and step-by-step perioperative management protocols.
Dayvigo Rebound Effects When Stopping: What the Clinical Evidence Actually Shows
A physician-reviewed, evidence-based guide to lemborexant (Dayvigo) rebound insomnia and discontinuation effects, covering mechanism, SUNRISE trial data, tapering strategies, and when to seek clinical support.
Dayvigo Renal Protection or Renal Risk: What the Clinical Evidence Shows
A physician-reviewed deep dive into lemborexant (Dayvigo) and kidney safety. Covers pharmacokinetics, CKD dosing, clinical trial data, and practical guidance for patients with renal impairment.
Dayvigo Restarting After Acute Illness: A Clinical Guide to Lemborexant
Learn exactly how and when to restart lemborexant (Dayvigo) after acute illness, with dose-adjustment guidance, drug-interaction checks, and primary-literature citations reviewed by the HealthRX medical team.
Dayvigo Seasonal Use Considerations: What Clinicians and Patients Need to Know
A clinical deep-dive into lemborexant (Dayvigo) seasonal use considerations, covering circadian light shifts, DST transitions, SAD overlap, dose timing, and drug interactions across all four seasons.
Dayvigo Sexual Function Impact: What the Evidence Actually Shows
A clinician-level review of lemborexant (Dayvigo) and sexual function, covering label findings, SUNRISE trial limits, orexin biology, and how to evaluate new symptoms.
Dayvigo Sleep Architecture Impact: What Lemborexant Actually Does to Your Sleep Stages
A clinician-level review of how lemborexant (Dayvigo) reshapes sleep architecture, from REM and slow-wave changes to next-morning function, with primary-trial citations throughout.
Dayvigo Travel & Timezone-Shift Protocols: A Clinical Guide to Using Lemborexant Across Time Zones
Board-reviewed clinical protocols for using lemborexant (Dayvigo) during travel and timezone shifts. Covers dosing timing, jet lag physiology, SUNRISE-1 data, and next-morning alertness considerations.